The Relationship of Vitiligo with Insulin Resistance and Metabolic Syndrome

Tabanlıoğlu-Onan, Duru; Hazar-Tantoğlu, Burcu; Artüz, Ferda; Hayran, Yıldız; Balamir, İlhan; Turhan, Turan

doi:10.5336/medsci.2018-60404

Cited by 1 publication

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Onan et al found remarkably higher levels of insulin and triglyceride levels in patients with vitiligo. However, no significant increase was found in the prevalence of insulin resistance or metabolic syndrome in their study [30]. Increased prevalence of vitiligo in type 2 diabetes patients has also been seen in some studies [31,32].…”

Section: Clinical Outcomesmentioning

confidence: 74%

Vitiligo: The Association With Metabolic Syndrome and the Role of Simvastatin as an Immunomodulator

Verma¹,

Hussain²,

Namiq³

et al. 2021

Cureus

View full text Add to dashboard Cite

Vitiligo is an autoimmune condition primarily affecting the skin where there is destruction of melanocytes characterized by pinkish-white patches on the skin. It is associated with other autoimmune diseases such as thyroid disease, rheumatoid arthritis, diabetes mellitus, and metabolic syndrome. Metabolic syndrome is a constellation of disorders including insulin resistance, hypertension, dyslipidemia, and obesity, and is considered a leading cause of cardiovascular morbidity. Simvastatin is a potent hypolipidemic drug that also possesses immunomodulating properties and is a common drug used in dyslipidemia and cardiovascular diseases. This study aimed to assess the association between vitiligo and metabolic syndrome and explore the immunomodulating properties of simvastatin for use in vitiligo. We reviewed various articles from PubMed, ResearchGate, and Google Scholar using different keywords and Medical Subject Headings and finalized 33 studies to be used in our review. The articles selected showed a positive association between vitiligo and metabolic syndrome or one of the component diseases of metabolic syndrome. The benefits of using simvastatin were also addressed by few articles attributing to its antioxidant and immunomodulating effect. However, there was no concrete explanation justifying the association between vitiligo and metabolic syndrome due to a limited number of studies and smaller sample size. Large-scale clinical trials should be conducted to evaluate the use of simvastatin as an immunomodulator in vitiligo to prevent possible metabolic complications.

show abstract

Section: Clinical Outcomesmentioning

confidence: 74%